| Identification | Back Directory | [Name]
4-(cyclohexyloxy)-2-(1-(4-[(4-Methoxybenzene)sulfonyl]piperazin-1-yl)ethyl)quinazoline | [CAS]
815592-21-3 | [Synonyms]
VRT325
VRT-325
VRT 325
CFcor325
CFcor-325
CFcor 325
4-cyclohexyloxy-2-[1-[4-(4-methoxyphenyl)sulfonylpiperazin-1-yl]ethyl]quinazoline
4-(Cyclohexyloxy)-2-[1-[4-[(4-methoxyphenyl)sulfonyl]-1-piperazinyl]ethyl]quinazoline
4-(cyclohexyloxy)-2-(1-(4-[(4-Methoxybenzene)sulfonyl]piperazin-1-yl)ethyl)quinazoline
Quinazoline, 4-(cyclohexyloxy)-2-[1-[4-[(4-methoxyphenyl)sulfonyl]-1-piperazinyl]ethyl]- | [Molecular Formula]
C27H34N4O4S | [MDL Number]
MFCD08360682 | [MOL File]
815592-21-3.mol | [Molecular Weight]
510.65 |
| Hazard Information | Back Directory | [Uses]
VRT-325 is a novel small molecule discovered by screening a compound library designed to address the genetic defect in cystic fibrosis (CF) caused by the ΔF508 mutation in CFTR. VRT-325 belongs to a class of compounds that promote ΔF508-CFTR efflux from the endoplasmic reticulum and restores chloride transport levels in epithelial cells of CF-derived bronchi[1]. | [References]
[1] Van Goor F, et al. Rescue of ?認508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules[J]. American Journal of Physiology-Lung Cellular and Molecular Physiology, 2006, 290(6): L1117-L1130. |
|
|